The philosophy of cancer treatment always has “pain, without gain” of the leg, and the closure of the directed path and the “tolerated maximum dose”, explained Ben Zestkind, co -founder, president and CEO of immuneration. Now Zijnkind and his clinical stage biotechnology company are trying to try something new in the field of pancreas cancer.
Instead of closing a road throughout the day and then dosing a patient at the maximum dose that can be tolerated, the company is developing a new approach that allows it to periodically turn off that route and then it is wrong or hits the time or blow. “” The first clinical results of this approach aimed at the mitogen activated -activated protein pathway (MAPK) are promising.
In our season 2 of the pivot podcast, tension from April to June, we focus on innovations in oncology, beginning with the high objective of the immune of making cancer manageable as a chronic disease.
You can see the whole video here:
